Investment Thesis
Dare Bioscience is in severe financial distress with a completely unsustainable business model characterized by $3.0M operating losses against only $152.5K in revenue, resulting in -1967% operating margins. The company is burning $5.5M annually in operating cash flow with only $18.5M cash on hand, providing approximately 3.5 years of runway at current burn rates, while stockholders' equity has collapsed to just $734.5K. Without imminent successful drug commercialization or significant capital injection, the company faces high bankruptcy risk and severe shareholder dilution.
Strengths
- Maintains $18.5M in cash providing near-term operational runway
- No long-term debt burden limiting financial obligations
- Revenue growth of 10429% YoY demonstrates early product traction
Risks
- Operating losses of $3.0M against revenue of $152.5K creates unsustainable -1967% operating margin
- Stockholders' equity of $734.5K is critically depleted; total assets ($27.8M) nearly equal liabilities ($27.1M)
- Operating cash burn of $5.5M annually with only 3.5 years of runway at current burn rate
- Net income deteriorated 230.6% YoY despite revenue growth, indicating worsening unit economics
- Current ratio of 1.03x provides minimal liquidity cushion above insolvency threshold
Key Metrics to Watch
- Monthly operating cash burn rate and runway extension timeline
- Product revenue contribution and gross margins once products commercialize
- Clinical trial outcomes and regulatory milestones for pipeline candidates
- Customer acquisition cost and customer lifetime value economics
- Financing activities and capital raising to extend runway
Financial Metrics
Revenue
152.5K
Net Income
-3.0M
EPS (Diluted)
$-0.21
Free Cash Flow
-5.5M
Total Assets
27.8M
Cash
18.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-1,967.1%
Net Margin
-1,967.7%
ROE
-408.5%
ROA
-10.8%
FCF Margin
-3,621.2%
Balance Sheet & Liquidity
Current Ratio
1.03x
Quick Ratio
1.03x
Debt/Equity
0.00x
Debt/Assets
97.4%
Interest Coverage
-9.30x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T08:03:29.972737 |
Data as of: 2026-03-31 |
Powered by Claude AI